Safety seen with AR-501, inhaled treatment for CF lung infections | Phase 2a trial also reports high levels of medicine in patients' sputum
AR-501 was well tolerated by adults with CF and chronic lung infections; higher concentrations in lungs than needed to resist P. aeruginosa.